A thymidine kinase (TK), inverted repeat, glycoprotein I (gI) and glycoprotein X (gpX) genedeleted modified live virus pseudorabies vaccine was evaluated for safety in swine and for efficacy in protecting swine against challenge with pseudorabies virus (PRV). Safety was evaluated by inoculating pregnant gilts intravenously and 3-day-old pigs intracerebrally with the vaccine. Efficacy was evaluated by 1) vaccinating 3-day-old pigs with a minimal protective dose intranasally and then challenging with PRV 3 weeks postvaccination or 2) vaccinating weaned pigs with a standard field dose intramuscularly and then challenging with PRV 4 weeks postvaccination. The pigs vaccinated intranasally remained clinically normal following vaccination and challenge with PRV. The pigs vaccinated intramuscularly remained clinically normal following vaccination, but mild respiratory signs were seen in some of the vaccinated pigs following challenge with PRV. Humoral immune response was evaluated with enzyme-linked immunosorbent assays (ELISAs) and a serum virus neutralization test. All of the intramuscularly vaccinated pigs became gI and gpX positive on differential ELISAs following challenge. All of the intranasally vaccinated pigs were seropositive on the indirect gI ELISA following challenge, but not all of the pigs were seropositive on the blocking gI ELISA or the gpX ELISA 3 weeks postchallenge.
second differential ELISA. This aspect of the vaccine becomes particularly important as the prevalence of pseudorabies declines in the USA and false-positive reactors become more common. The purpose of this research was to evaluate the safety of this vaccine in A new gene-deleted modified live virus pseudorabies (PR) vaccine (vaccine A a ) has been developed for use in swine. Previous work has shown that deletion of portions of the pseudorabies viral genome reduces the virulence of the virus. l,7 Deletions of the thymidine kinase (TK) gene and inverted repeats of vaccine A were made to reduce the virulence of the modified live vaccine virus. In addition, the genes coding for the diagnostic glycoproteins I (gI) and X (gpX) were also deleted. In current vaccines, a single deletion of one of the genes coding for gI, gIII, or gpX has allowed investigators to serologically distinguish vaccinates from field-infected pigs using enzyme-linked immunosorbent assays (ELISAS). 8, 14, 16, 17 Vaccine A, however, is the first PR vaccine virus with deletions of two of the genes coding for diagnostic glycoproteins. Swine vaccinated with this product do not produce either gI or gpX antibodies and, in the absence of pseudorabies virus (PRV) infection, are seronegative on both gI and gpX ELISAs. 12 Either gI or gpX differential ELISAs can be used to test serum from animals given vaccine A. In addition, the deletion of two diagnostic antigens from vaccine A allows for samples to be evaluated with one of the differential ELISAs and the results confirmed with the gestating gilts and young pigs, the efficacy of intranasal and intramuscular vaccination, and the humoral immune response.
Materials and methods

Experimental animals and procedures
Animals and housing. All pigs were obtained from pseudorabies-free herds and were housed in isolation facilities throughout the course of the experiment. Weanling age and older pigs were tested for the presence of PRV antibodies on the screening ELISA test b at the time they were placed in isolation facilities, and the sows of nursing piglets were tested at the time the piglets were started on an experiment.
Virus. The virus strain used in the challenge experiments
was a pneumotropic strain, VDL 4892. 2 Virus was propagated on Madin-Darby bovine kidney (MDBK) cells grown at 37 C in 162-cm 2 flasks c containing minimum essential medium d supplemented with 1,000 µg/ml of amphotericin B, e 50 µg/ml of gentamicin sulfate, f and 5% fetal calf serum. g Flasks were inoculated with VDL 4892 when the MDBK cell monolayer was 80-90% confluent. The virus was grown for 48 hr then harvested by freezing and thawing the flask 2 times and centrifuging at 1,400 x g. The virus-containing supernatant was stored at -70 C.
Challenge virus was titrated at the time pigs were challenged. Tenfold dilutions of the virus solution were made. Fifty microliters of each virus dilution and 150 µ1 of MDBK cells were added to 8 wells of a microtiter plate, h incubated at 37 C in a 5% CO 2 atmosphere for 48 hr, and examined for typical cytopathic effect (CPE). The titer was calculated using the Karber method. 9 The virus was given intranasally using a 3-cc syringe fitted with a 16-gauge needle that had been shortened to approximately 5 mm. Latex tubing i 1.6 mm x 0.8 mm was cut into a 35mm length and placed over the cut needle to facilitate deposition of the virus in the nasal cavity. One half of the challenge inoculum was administered into each nostril.
Vaccines. Vaccine A was a modified live virus (MLV)
PRV vaccine in which the genes coding for the gI and gpX antigens were deleted (Table 1) . Vaccine B was an MLV PRV gpX gene-deleted vaccine, and Vaccine C k was an MLV PRV gI gene-deleted vaccine.
Serology. Serum samples were tested with commercially available PRV ELISAs: a screen assay licensed for use in nonvaccinated pigs, a gpX assay 1 for pigs vaccinated with vaccines A or B, a blocking gI assay m for pigs vaccinated with vaccines A or C, and an indirect gI assay n for pigs vaccinated with vaccine C (Table 1) . Antibody titers were determined using a serum virus neutralization (SVN) test. Sera were heat inactivated for 30 min at 56 C. Twofold dilutions of each serum sample were made in 96-well microtiter plates using minimum essential medium supplemented with 1,000 µg/ml of amphotericin B and 50 µg/ml of gentamicin sulfate. An equal volume of Shope strain PRV was added to each well at a dose of 100-300 TCID 50 /well. After a 1 -hr incubation at room temperature, MDBK cells were added to each well at a sufficient concentration to give a complete monolayer at 48 hr. Plates were incubated at 37 C for 48 hr in a 5% CO, atmosphere. The antibody titer was reported as the highest dilution at which there was 100% neutralization of the virus.
Nasal swabs. Sterile dacron swabs o were moistened in
Earle's medium d supplemented with sodium bicarbonate and antibiotics (1,000 µg/ml of amphotericin B and 50 µg/ml of gentamicin sulfate). Both nostrils were swabbed with a single swab. The swab was then placed into 2 ml of the supplemented Earle's medium.
Virus isolation. Tissue homogenates and nasal swab samples were centrifuged at 2,000 x g for 15 min. Two hundred microliters of the supernatant from tissue homogenates was placed in duplicate wells of 24-well cell culture plates containing MDBK cells. Samples were incubated for 1 hr at 37 C in a 5% CO 2 atmosphere, after which the medium was removed from each well and replaced with Eagle's minimum essential medium containing 2% fetal calf serum, 1,000 µg/ ml of amphotericin B, and 50 µg/ml of gentamicin sulfate. Plates were observed daily for 1 wk for typical CPE. All plates containing wells with no viral activity were frozen at -70 C and then thawed at 37 C. Medium from duplicate wells was mixed, and 200 µ1 of this mixture was inoculated in duplicate on 24-well cell culture plates. Wells were observed for an additional week and then discarded if no CPE was observed.
Virus detection in tissues of dead pigs. All challenged pigs that died were necropsied, and tissues were collected for detection of PRV. Tonsils were collected for the fluorescent antibody test, 5 and brain, lung, and spleen tissues were collected for virus isolation.
Plaque assay. Quantitation of virus from nasal swabs was determined using a slightly modified version of the previously described plaque assay technique. 4 All sample dilutions were inoculated (0.1 ml/dish) into 3 60,mm cell culture dishes. The average plaque count of dishes with ≥ 10 plaques and ≤ 100 plaques was used for titration calculations.
Experimental design
Experiment 1. Eleven pregnant gilts were inoculated intravenously with a single 2-ml field dose of vaccine A at 40-75 days of gestation. Blood samples were collected at the time of inoculation and 4 wk postvaccination. Gilts were observed daily from the time of inoculation until the time of farrowing. Experiment 2. Four 3-day-old pigs were inoculated intracerebrally with a field dose of vaccine A that was reconstituted to 0.2 ml/dose. An additional 4 pigs in the litter served as contact controls. All pigs were weighed on days 0, 7, and 21. The pigs were observed and rectal temperatures were recorded daily for 21 days. Blood samples were collected from all pigs in the litter at the end of the study. Experiment 3. Twenty pigs were given a single 2-ml minimal dose containing 0.01 times the standard field dose of vaccine A intranasally at 3 days of age. Each pig received 1 ml/nostril. Nasal swabs were collected on days 3, 6, 9, and 12 postvaccination and processed for virus isolation. At 23 days postvaccination, the 20 vaccinated pigs and 5 nonvaccinated control pigs were challenged intranasally with a l-ml dose (2.3 x 10 5 TCID50/ml) of VDL 4892 PRV. Each pig received 0.5 ml/nostril. Nasal swabs were collected on days 3, 6, 9, and 12 postchallenge, and virus was quantitated by plaque assay. Blood samples were collected at the time of challenge and on days 7, 10, 14, and 23 postchallenge. Pigs were observed daily and clinical signs were recorded. Experiment 4. Four groups of weaned pigs were vaccinated intramuscularly with vaccine A (n = 10), vaccine B (n = 10), or vaccine C (n = 10) or were kept as nonvaccinated controls (n = 10). Each group was housed separately. All pigs were challenged with 0.5 ml/nostril of VDL 4892 PRV (2.3 x 10 5 TCID 50 /ml) on day 31 postvaccination. Pigs were observed daily and nasal swabs were collected on days 3, 6, 9, and 12 postchallenge. Virus was quantitated using a plaque assay method. Blood samples were collected from pigs on days 7, 14, and 20 postchallenge.
Results
Experiment 1. All 11 gilts remained clinically normal throughout gestation, and no adverse reactions were observed after the intravenous inoculation of vaccine A. Normal litters were observed in all females, with an average of 9.1 pigs delivered and 8.0 pigs born live. All 11 gilts were seropositive for pseudorabies antibodies on the screening ELISA 4 weeks postvaccination but were seronegative on the blocking gI ELISA. Serum virus neutralization antibody titers were ≤ 1:4. Experiment 2. The 4 intracerebrally vaccinated pigs and 4 contact control littermates remained clinically normal throughout the 3-week observation period. The mean rectal temperature for the vaccinated pigs was 38.9 C (range, 38.2-39.9 C), and the mean rectal temperature for the control pigs was 38.7 C (range, 38.0-39.7 C). The average weight gain for both the vaccinated and control pigs was 0.2 kg/day during the 21. day period. Two of the vaccinated pigs showed a weak antibody response on the screening ELISA and the latex agglutination test 21 days postinoculation but were seronegative on the 3 differential tests and the SVN test.
Experiment 3. Of 20 intranasally vaccinated pigs, 3 shed virus during the first 6 days postvaccination. The vaccinated pigs appeared clinically normal postvaccination and postchallenge. Clinical signs in the control pigs included depression, dyspnea,' nasal discharge, incoordination, tremors, and seizures. One control pig died on day 6 postchallenge, and a second pig died on day 8 postchallenge. The tonsils of both pigs were positive for PRV by the fluorescent antibody test. Virus was isolated from the brains of both pigs, but not from the lungs or spleens. Two of the remaining 3 control pigs continued to exhibit incoordination at the end of the 14-day observation period.
Quantitation of virus excreted by intranasally vaccinated and nonvaccinated pigs postchallenge revealed that vaccinated pigs excreted less virus, with an average of 10 1.0 plaque-forming units (PFU)/ml of virus on day 3 postchallenge, whereas the nonvaccinated pigs excreted 10 2.5 PFU/ml of virus. An analysis of variance 10 indicated that the amount of virus shed was significantly reduced (P < 0.03) in the vaccinated pigs versus the control pigs. In addition to shedding less virus, vaccinated pigs shed virus for a shorter length of time. Only 5% of vaccinated pigs were shedding virus on day 6 postchallenge, whereas all control pigs were still shedding virus. By day 9 postchallenge, the vaccinated pigs were no longer shedding, whereas all of the control pigs continued to shed virus.
Sera were tested for the presence of PRV antibodies using the SVN, gX, and both gI tests. Eighteen of the 20 intranasally vaccinated pigs were seropositive for PRV antibodies on the screening ELISA at the time of challenge, and 7 pigs had SVN titers ranging from 1:2 to 1:4 ( Table 2 ). The results for the intranasally vaccinated pigs on the differential tests are shown in Fig.  1 . Control pigs were negative on the differential tests Clinical signs in the vaccinated pigs postchallenge were respiratory in nature and included sneezing, coughing, and nasal discharge. Ten percent of the vaccine A pigs, 30% of the vaccine B pigs, and 20% of the vaccine C pigs developed clinical signs associated with the respiratory tract. One vaccine A pig developed swollen joints and was lame on day 9 postchallenge. A draining lesion developed on the left lateral thigh, and the pig had difficulty rising; therefore, the animal was euthanized on day 11 postchallenge. One vaccine C pig appeared incoordinated for 1 day and had muscle tremors for an additional 2 days before returning to normal. Seventy percent of the control pigs developed clinical signs related to the central nervous system, and 50% of the control pigs died as a result of pseudorabies infection.
On day 3 postchallenge, 100% of the control pigs, 60% of the vaccine A pigs, and 80% of the vaccine B and vaccine C pigs were shedding virus. The average amount of virus shed on day 3 postchallenge was 10 1.5 PFU/ml for the vaccine B pigs and 10 1.7 PFU/ml for both the vaccine A and vaccine C pigs. In contrast, the average titer of virus shed by the control pigs on day 3 postchallenge was 10 2.5 PFU/ml. On day 6 postchallenge, 10% of the vaccine A and vaccine B pigs and 89% of the control pigs were still shedding virus. The vaccinated and control pigs were no longer shedding virus by day 9 postchallenge. An analysis of variance using the Duncan multiple range test 11 suggested a significant difference (P < 0.03) in the amount of virus shed by the control pigs compared with that shed by the vaccinated pigs, but there was no difference among groups of vaccinated pigs in the amount of virus shed.
Sera from swine vaccinated with vaccine A or vaccine B were tested for the presence of antibody against gpX, and sera from animals vaccinated with vaccine brains. Both studies showed that TK-negative PRV A or vaccine C were tested for the presence of antibody had the ability to undergo limited replication in neural against gI (Table 3) . Serum virus neutralization titers tissue. Van Oirschot et al. suggested that, because pigs for the vaccinated pigs are shown in Table 4 . Prior to < 1 week old are highly susceptible to PRV, the absence challenge, 1 vaccine B pig and 1 vaccine A pig had a of clinical signs postvaccination is a good indicator of SVN titer of 1:2. The remaining vaccinated pigs had the avirulence of a vaccine. 18 If this hypothesis is true, no detectable SVN titers at the 1:2 dilution. No SVN then the clinical appearance of the pigs throughout the titers were detected in control pigs until day 14 post-trial indicated that intracerebral inoculation was not challenge, at which time SVN titers ranged from 1:4 detrimental to the pigs and that vaccine A was safe for to 1:16. use in 3-day-old pigs. The second objective of this research was to assess the protection conferred by vaccine A after intranasal (IN) or intramuscular (IM) vaccination. Intranasally vaccinated pigs were protected against clinical disease when challenged with virulent PRV, whereas the nonvaccinated pigs were not. In addition, the amount of virus shed and the period of viral shedding were both reduced in vaccinated animals. In contrast, the nonvaccinated pigs developed clinical signs of pseudorabies, had lower SVN antibody titers, and secreted larger amounts of virus and for a longer period of time.
Discussion
The first objective of this research was to assess the safety of vaccine A in gestating gilts and young pigs. Vaccine A did not adversely affect reproduction when given intravenously to pregnant gilts. Gilts inoculated with vaccine A far-rowed an average of 8.0 liveborn pigs. Three-day-old pigs inoculated intracerebrally with vaccine A were clinically healthy throughout the trial. No significant differences in behavior, rate of weight gain, or body temperature were observed between intracerebrally inoculated pigs and contact control pigs. The single difference noted between the two groups was seroconversion by 2 of the vaccinated pigs on the screening ELISA. Seroconversion provided evidence that vaccine A virus was able to undergo limited replication and stimulate a detectable immune response when given intracerebrally. Tenser et al. 13 examined PRV replication in trigeminal ganglia of mice, and Lomniczi et al. 6 examined PRV replication in chicken Intramuscularly vaccinated pigs were protected by each of the 3 vaccines tested, as compared with the nonvaccinated pigs. There was no difference in clinical signs among vaccine groups, with the exception of 1 animal in the vaccine C group that developed some incoordination. Both the vaccinated and control pigs shed virus for the first 6 days postchallenge, but by day 6 there were fewer vaccinated than nonvaccinated pigs shedding virus. The analysis of variance revealed a significant difference between the amount of virus shed by the vaccinated animals and that shed by the control animals. Based on protection against clinical disease, reduction in the duration of viral shedding, and a decrease in the amount of virus shed postchallenge, the efficacy of vaccine A was comparable to that of vaccine B and vaccine C when given IM. There were several differences between the IN vaccination trial and the IM vaccination trial. Animals vaccinated IM with vaccine A received 100 times more vaccine virus than did the IN vaccinated pigs. Even though the IN pigs received less vaccine virus, 35% of these pigs developed SVN antibody titers ≥ 1:2 approximately 3-4 weeks postvaccination compared with only 10% of the IM vaccinated pigs. In contrast, the mean antibody titers postchallenge were higher in the IM vaccinated pigs than in the IN vaccinated pigs. In addition, the IN vaccinated pigs had delayed antibody responses on the 3 differential tests as compared with the IM vaccinated pigs. Both groups of pigs were challenged with the same dose and strain of PRV, but viral shedding on day 3 postchallenge was different between the 2 groups. On day 3 postchallenge, 35% of the IN vaccinated pigs shed virus with a mean of 10 1.0 PFU/ ml, whereas 60% of the IM vaccinated pigs shed a mean of 10 1.7 PFU/ml. Intranasal vaccination has been used in some herds to increase the protective immune response at the site of initial virus entry and replication and to enhance the active immune response when passive immunity is present. 3, 15 Results from this study indicate that the presence of a protective immune response at the site of initial replication was important in reducing the amount of virus secreted nasally and may also be responsible for the delay in serologic response on the differential ELISAs and SVN tests. challenge with virulent PRV in animals vaccinated with 1 of the 3 vaccines included in the study. A difference was observed in PRV antibody detection among the 3 differential ELISAs. The gpX test took longer to identify 100% of the pigs as infected than did either of the gI tests. When the antibody responses of vaccine A and vaccine C vaccinated pigs were examined on an individual gI test, there was no difference between the response of one vaccinated group and those of the other vaccinated group. However, a comparison of the two gI tests showed differences. The indirect gI test detected infection-induced antibody at an earlier stage (40% of the pigs by day 7 postchallenge) and classified 100% of the pigs as infected by day 14 postchallenge. In contrast, none of the infected pigs were positive by the blocking gI test at day 7 postchallenge, and even at day 14 postchallenge only 90% were positive. Obviously, differences in test performance are an important consideration both in the diagnostic setting and for the veterinarian assisting a producer in eliminating PRV.
These experiments provided evidence that vaccine A is safe in gestating animals and young pigs. Upon challenge, both IN and IM vaccinated pigs were protected against virulent PRV, indicating that vaccine A was effective in preventing clinical pseudorabies. In addition, vaccine A provided increased diagnostic flexibility because of the dual deletion of envelope glycoproteins I and X. Animals vaccinated with vaccine A can be differentiated from field virus-infected animals using currently available gI or gX differential ELISA kits.
Sources and manufacturers
a. PRV/Marker Gold TM , SyntroVet, Inc., Lenexa, KS. b. HerdChek TM : Anti-PRV(S), IDEXX Laboratories, Westbrook, ME.
The third objective of this research was to monitor and compare the humoral immune response following 
